Daiwa Securities Group Inc. Atara Biotherapeutics, Inc. Transaction History

Daiwa Securities Group Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 31, 2023	SELL	$1.5 - $3.04 $23,065 - $46,746	-15,377 Reduced 98.15%	290 $0
Q1 2023 May 02, 2023	BUY	$2.8 - $5.46 $8,456 - $16,489	3,020 Added 23.88%	15,667 $45,000
Q4 2022 Feb 06, 2023	BUY	$2.85 - $5.18 $3,950 - $7,179	1,386 Added 12.31%	12,647 $41,000
Q3 2022 Nov 02, 2022	SELL	$2.85 - $8.73 $8,470 - $25,945	-2,972 Reduced 20.88%	11,261 $43,000
Q2 2022 Aug 09, 2022	BUY	$4.69 - $9.84 $65,392 - $137,199	13,943 Added 4807.93%	14,233 $111,000
Q3 2021 Nov 05, 2021	BUY	$11.99 - $17.9 $1,726 - $2,577	144 Added 98.63%	290 $5,000
Q4 2020 Feb 04, 2021	SELL	$12.67 - $26.23 $3,319 - $6,872	-262 Reduced 64.22%	146 $3,000
Q3 2020 Nov 02, 2020	BUY	$11.92 - $15.87 $1,215 - $1,618	102 Added 33.33%	408 $5,000
Q4 2019 Jan 31, 2020	SELL	$10.89 - $16.79 $392 - $604	-36 Reduced 10.53%	306 $5,000
Q3 2019 Nov 04, 2019	BUY	$12.03 - $19.94 $577 - $957	48 Added 16.33%	342 $5,000
Q1 2019 Apr 26, 2019	BUY	$28.4 - $41.74 $2,442 - $3,589	86 Added 41.35%	294 $12,000
Q1 2018 May 02, 2018	BUY	$18.0 - $48.35 $3,744 - $10,056	208 New	208 $8,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

Stay updated on Daiwa Securities Group Inc. with notifications on news.